Larsulin Cartridge

Indications

Larsulin serves to enhance glycemic control among both adults and children diagnosed with type 1 diabetes mellitus, as well as adults diagnosed with type 2 diabetes mellitus.

Pharmacology

Larsulin, comprising Insulin Glargine, constitutes a sterile solution intended for subcutaneous injection. Insulin glargine, a synthetic analogue of human insulin developed through recombinant DNA technology, acts as a sustained (up to 24-hour duration) blood glucose-lowering agent. Its primary function involves regulating glucose metabolism by promoting peripheral glucose uptake, mainly by skeletal muscle and adipose tissue, and by curbing hepatic glucose production. Additionally, insulin and its analogues inhibit lipolysis and proteolysis while fostering protein synthesis.

Dosage

With a relatively consistent glucose-lowering profile spanning 24 hours, Insulin Glargine facilitates once-daily dosing. Although it may be administered at any time of day, maintaining a consistent administration time daily is advised. Individualization of Insulin Glargine dosage based on clinical response is crucial, with continuous blood glucose monitoring being imperative for all diabetic patients. For type 1 diabetes patients, Insulin Glargine should be integrated into regimens alongside short-acting insulin. It’s important to note that intravenous administration of Insulin Glargine is not recommended due to the potential for severe hypoglycemia.

Administration

Insulin Glargine should be administered subcutaneously once daily at a consistent time every day. Whether using a cartridge or vial, proper handling and preparation procedures must be followed to ensure efficacy and safety.

Interaction

Various medications can influence glucose metabolism, potentially necessitating dose adjustments. Noteworthy interactions include those with oral anti-diabetic products, ACE inhibitors, fibrates, and others, which may either reduce or increase Larsulin requirements.

Contraindications

Insulin glargine is contraindicated in individuals with hypersensitivity to insulin glargine or any of its components.

Side Effects

Potential side effects of Larsulin encompass hypoglycemia, allergic reactions, injection site reactions, and others.

Pregnancy & Lactation

Usage of Insulin Glargine during pregnancy should be carefully weighed against potential fetal risks, while caution is advised during lactation due to potential excretion of Insulin Glargine in human milk.

Precautions & Warnings

Close monitoring of blood glucose levels is essential for all patients using Larsulin. Dilution or mixing with other insulin products or solutions should be avoided. Caution is warranted in patients with renal or hepatic impairment, as dose adjustments may be necessary.

Overdose Effects

Overdosing on Larsulin may lead to hypoglycemia, necessitating appropriate intervention depending on the severity of the episode.

Therapeutic Class

Larsulin falls under the category of Long-Acting Insulin.

Storage Conditions

Proper storage of Larsulin involves refrigeration at 2°C to 8°C, safeguarded from freezing and light exposure.